


1634
PATENT *Image*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Re application of: Ewing et al.

Application No.: 09/811,283

Filed: March 15, 2001

Attorney Docket No.: CAMIP005

Examiner: Fredman, Jeffrey Norman

Group: 1634

Title: PREDICTING METABOLIC STABILITY
OF DRUG MOLECULES

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first-class mail on December 9, 2003 in an envelope addressed to the Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.

Signed: _____

Leslie Russell
Leslie Russell

**INFORMATION DISCLOSURE STATEMENT WITH STATEMENT
UNDER 37 CFR §§1.56 AND 1.97**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The references listed in the attached PTO Form 1449 copies of which are enclosed, may be material to the examination of the above-identified patent application. These references were cited in a corresponding EPC application. A copy of the European Search Report which was dated September 11, 2003, is enclosed herewith as well. These references are submitted in compliance with the applicant's duty of disclosure pursuant to 37 CFR §§1.56 and 1.97. Accordingly, the Examiner is requested to make these citations official record in this application.

This Information Disclosure Statement is not to be construed as a representation that additional information (material to the examination of this application) does not exist or that the enclosed reference(s) constitute prior art.

Statement under 37 CFR § 1.97(e)

The undersigned hereby states that the references enclosed herewith were cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. (37 CFR 1.97(e)(1))

Accordingly, it is respectfully submitted that no fee is due in conjunction with the filing of this IDS. However, should the Commissioner determine that additional fees are required for

filing the present Information Disclosure Statement, the Commissioner is hereby authorized to charge any such fees to our deposit account number 500388 (Order No. CAMIP005).

Respectfully submitted,


BEYER WEAVER & THOMAS, LLP

A handwritten signature in black ink, appearing to read "Jeffrey K. Weaver", with a long horizontal flourish extending to the right.

Jeffrey K. Weaver

Registration No. 31,314

P.O. Box 778
Berkeley, CA 94704-0778



Form 1449 (Modified) Information Disclosure Statement By Applicant (Use Several Sheets if Necessary)	Atty Docket No. CAMIP005 Applicant: Ewing et al. Filing Date March 15, 2001	Application No.: 09/811,283 Group 1635
----------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------	-----------------------------------------------------

U.S. Patent Documents

Examiner Initial	No.	Patent No.	Date	Patentee	Class	Sub-class	Filing Date
	A1	5,798,275	8/25/98	Kauvar et al.			
	A2	5,859,972	1/12/99	Subramaniam et al.			
	A3	6,081,766	6/27/00	Chapman et al.			

Foreign Patent or Published Foreign Patent Application

Examiner Initial	No.	Document No.	Publication Date	Country or Patent Office	Class	Sub-class	Translation	
							Yes	No
	B1	WO 00/08205	02/17/00	PCT				

Other Documents

Examiner Initial	No.	Author, Title, Date, Place (e.g. Journal) of Publication
	C1	Karickhoff et al., "Predicting Chemical Reactivity by Computer," Environmental Toxicology and Chemistry, Vol. 10, pp. 1405-1416 (1991)
Examiner		Date Considered

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.